GET DAILY SIGNALSRyan Specialty (RYAN) Delivers Q3 Earnings Beat with Steady Organic Growth
Key Takeaways
- Ryan Specialty reported third quarter 2026 total revenue of $790.0 million, up 4.7% from $754.6 million a year earlier, though slightly below consensus estimates.
- Adjusted (non-GAAP) diluted earnings per share came in at $0.51, beating the analyst consensus of $0.49 by $0.02.
- GAAP net income rose 40.6% to $88.0 million, with diluted earnings per share of $0.29.
- Organic revenue growth was 4.0% for the quarter, while Adjusted EBITDAC grew 3.8% and Adjusted Diluted EPS rose 8.5%.
- The company maintained its full-year 2026 mid-single-digit organic revenue growth guidance and updated its Adjusted EBITDAC margin outlook to a modest decline versus 2025.
- For more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the dedicated pages available for RYAN.
- You can also discover automated strategies and market opportunities by exploring Trending AI Robots.
Earnings Context and Why It Matters
Ryan Specialty Holdings is a leading international specialty insurance firm serving brokers, agents, and carriers. Its third quarter 2026 results carry added weight because they arrived against the company's toughest year-over-year comparison, offering investors a clearer read on how durable its growth engine remains in a more competitive specialty market. The quarter tested both revenue momentum and margin discipline, two pillars of the company's investment thesis. With organic growth slowing modestly from prior peaks and expense management under scrutiny, the report served as a key checkpoint on whether Ryan Specialty could keep expanding profitability while continuing to invest in talent and platform capabilities. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter ended September 30, 2026, Ryan Specialty reported total revenue of $790.0 million, an increase of 4.7% from $754.6 million in the prior-year period. Organic revenue growth was 4.0% for the quarter. GAAP net income climbed 40.6% to $88.0 million, up from $62.6 million a year earlier, translating to basic earnings per share of $0.30 and diluted earnings per share of $0.29.
On an adjusted (non-GAAP) basis, diluted earnings per share reached $0.51, exceeding the consensus estimate of $0.49 by $0.02. Revenue, however, came in slightly below the consensus figure of roughly $793.6 million. Adjusted EBITDAC (earnings before interest, taxes, depreciation, amortization, and change in contingent consideration) grew 3.8%, while Adjusted Diluted EPS rose 8.5%. The company noted its Adjusted EBITDAC margin was down only 30 basis points year to date, reflecting disciplined expense management.
Market Reaction and Investor Sentiment
Heading into the report, sentiment around Ryan Specialty reflected a cautious market environment, with the company's shares trading lower over the trailing three- and twelve-month periods. The results presented a mixed picture for investors: an adjusted earnings beat underscored resilient profitability and cost control, while the modest revenue miss relative to consensus highlighted softer top-line momentum than analysts had modeled. The company's maintained mid-single-digit organic growth guidance for 2026 signaled confidence in its core franchise, though the updated outlook for a modestly lower Adjusted EBITDAC margin pointed to continued investment-related cost pressure. Net-net, the quarter reinforced the narrative of a durable, scalable platform performing steadily through a more challenging specialty insurance cycle. From what I see, this balance between earnings strength and revenue moderation is worth watching closely.
Forward Outlook and Key Factors to Monitor
Ryan Specialty maintained its full-year 2026 guidance for mid-single-digit organic revenue growth, a signal that management expects its broking and underwriting businesses to keep expanding despite a tougher competitive backdrop. At the same time, the company updated its outlook to expect an Adjusted EBITDAC margin that is down modestly for 2026 compared to the prior year, reflecting ongoing investments in talent and platform capabilities.
Investors will want to monitor several themes in the quarters ahead. First, watch whether organic revenue growth can reaccelerate or stabilize as prior-year comparisons ease. Second, keep an eye on margin trends, since continued hiring and platform spending could pressure profitability even as revenue grows. Third, the pace of capital returns matters: the company returned roughly $173.7 million to shareholders in the quarter and still has buyback capacity remaining, which could support the stock if execution stays steady.
Finally, broader specialty insurance conditions—including pricing, catastrophe activity, and carrier underwriting appetite—will shape demand for Ryan Specialty's products and services. The company ended the quarter with $168.8 million in cash and $3.7 billion in outstanding debt principal, so balance-sheet management and interest costs remain relevant factors to track. I’m watching this closely as the next few quarters should clarify whether these investments translate into sustained momentum.
Exploring AI Tools for Portfolio Insights
In my view, incorporating data-driven tools into routine analysis helps surface patterns that might otherwise go unnoticed. I recently used Tickeron’s AI Screener to review comparable names in the specialty insurance space and refine my screening criteria around growth metrics and margin trends. This approach added useful context without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RYAN in upward trend: 10-day moving average moved above 50-day moving average on October 23, 2026
The 10-day moving average for RYAN crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on RYAN as a result. In 56 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for RYAN just turned positive on October 05, 2026. Looking at past instances where RYAN's MACD turned positive, the stock continued to rise in 24 of 43 cases over the following month. The odds of a continued upward trend are 56%.
RYAN moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where RYAN advanced for three days, in 198 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 137 of 249 cases where RYAN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The 10-day RSI Indicator for RYAN moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 19 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
RYAN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. RYAN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RYAN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: RYAN's P/B Ratio (10.372) is slightly higher than the industry average of (2.653). RYAN has a moderately high P/E Ratio (55.487) as compared to the industry average of (18.087). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.322). Dividend Yield (0.012) settles around the average of (0.045) among similar stocks. P/S Ratio (1.707) is also within normal values, averaging (2.968).
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry InsuranceBrokersServices
Advertisement